VetCell

Pipeline

Stem Cell research is progressing at an exciting pace. The bulk of this work is targeted at human medicine but much of the research is equally applicable to veterinary medicine. Being at the forefront of veterinary stem cell technology VetCell is well placed to take advantage of the opportunities as they arise.

VetCell is working with the Royal Veterinary College, other research establishments, and key individuals to encourage the development of clinically applicable, and commercially viable, stem cell technologies for the animal health sector.

Commercially viable services will be developed that are targeted at the growing small animal market as well as the performance horse market.

VetCell will be able to rapidly bring new products / services to the global market via the established international network of commercial partners.

Future services are likely to be targeted at cardiac disease, a range of joint and bone disorders, and a number of cancers.

VetCell has established a strong IP position in veterinary stem cell technology. The Company has committed to fully protect its intellectual property position and currently owns or has exclusive licences to a number of internationally pending patents. Foreign counterparts to these patents have been filed in Europe, the US, the Far East, the Middle East, South America and Australia.

These patents span the major aspects of the isolation, manufacture and therapeutic veterinary uses of mesenchymal stem cells. Based on this portfolio, VetCell believes it has a clear and unencumbered path to commercialization of its MSC-based therapeutic products and that competitors developing similar stem cell products will require a license to practice the intellectual property protected by the Company. We are confident that our current patent portfolio provides exclusive entry into our target markets.


.
.
w	.
		Pipeline Stem Cell research is progressing at an exciting pace. The bulk of this work is targeted at human medicine but much of the research is equally applicable to veterinary medicine. Being at the forefront of veterinary stem cell technology VetCell is well placed to take advantage of the opportunities as they arise. VetCell is working with the Royal Veterinary College, other research establishments, and key individuals to encourage the development of clinically applicable, and commercially viable, stem cell technologies for the animal health sector. Commercially viable services will be developed that are targeted at the growing small animal market as well as the performance horse market. VetCell will be able to rapidly bring new products / services to the global market via the established international network of commercial partners. Future services are likely to be targeted at cardiac disease, a range of joint and bone disorders, and a number of cancers. IP VetCell has established a strong IP position in veterinary stem cell technology. The Company has committed to fully protect its intellectual property position and currently owns or has exclusive licences to a number of internationally pending patents. Foreign counterparts to these patents have been filed in Europe, the US, the Far East, the Middle East, South America and Australia. These patents span the major aspects of the isolation, manufacture and therapeutic veterinary uses of mesenchymal stem cells. Based on this portfolio, VetCell believes it has a clear and unencumbered path to commercialization of its MSC-based therapeutic products and that competitors developing similar stem cell products will require a license to practice the intellectual property protected by the Company. We are confident that our current patent portfolio provides exclusive entry into our target markets.